O
BMY.RT

OrbiMed’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

OrbiMed’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400,000
Closed -$276K – 188
2020
Q4 		$276K Hold
400,000
– – ﹤0.01% 149
2020
Q3 		$900K Buy
400,000
+50,000
+14% +$143K 0.01% 140
2020
Q2 		$1.25M Hold
350,000
– – 0.02% 132
2020
Q1 		$1.33M Hold
350,000
– – 0.02% 130
2019
Q4 		$1.05M Buy
+350,000
New +$910K 0.02% 130

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

OrbiMed's BMY.RT Position: Q1 2021 in Review

OrbiMed sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 400,000 shares — an estimated $276K sold.

OrbiMed first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.33M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • OrbiMed reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • OrbiMed sold 400,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $276K.
  • OrbiMed first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • OrbiMed's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.33M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.